Aquestive Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AQUESTIVE, and when can generic versions of AQUESTIVE drugs launch?
AQUESTIVE has two approved drugs.
There are four US patents protecting AQUESTIVE drugs.
There are one hundred and seventy-three patent family members on AQUESTIVE drugs in twenty-three countries.
Summary for Aquestive
International Patents: | 173 |
US Patents: | 4 |
Tradenames: | 2 |
Ingredients: | 2 |
NDAs: | 2 |
PTAB Cases with Aquestive as petitioner: | See PTAB cases with Aquestive as petitioner |
Drugs and US Patents for Aquestive
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aquestive | SYMPAZAN | clobazam | FILM;ORAL | 210833-001 | Nov 1, 2018 | RX | Yes | No | 8,603,514 | See Plans and Pricing | Y | See Plans and Pricing | |||
Aquestive | SYMPAZAN | clobazam | FILM;ORAL | 210833-003 | Nov 1, 2018 | RX | Yes | Yes | 8,765,167 | See Plans and Pricing | Y | See Plans and Pricing | |||
Aquestive | ZUPLENZ | ondansetron | FILM;ORAL | 022524-001 | Jul 2, 2010 | DISCN | Yes | No | 8,580,830 | See Plans and Pricing | Y | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Aquestive Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 2011017484 | See Plans and Pricing |
Japan | 2008515403 | See Plans and Pricing |
Denmark | 1463491 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.